The Interim Decides: Why Clinical Trial Data Cleanliness Cannot Wait for the Final Readout
Blog The Interim Decides: Why Clinical Trial Data Cleanliness Cannot Wait for the Final Readout BMS, argenx, and BioNTech show that the fate of a clinical program is increasingly decided at the interim analysis, not the final readout. For bioanalytical labs and CROs, that means data has to be clean on the day of the…